NCT06843148View on ClinicalTrials.gov

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

NANot yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

July 31, 2030

Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Liver Fibrosis/NASHNon-Alcoholic Steato-Hepatitis (NASH)
Interventions
DRUG

Niacin (250mg)

"Niacin will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:~* Week 1: 250mg~* Week 2: 500mg~* Week 3 to Week 12: 750mg (3 x 250mg caplets)"

DRUG

Placebo Oral Tablet

"Placebo will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:~* Week 1: 250mg~* Week 2: 500mg~* Week 3 to Week 12: 750mg (3 x 250mg caplets)"

Trial Locations (1)

J1H 5N4

Centre de recherche du CHUS, Sherbrooke

All Listed Sponsors
collaborator

Centre hospitalier universitaire de Québec- Université Laval

UNKNOWN

collaborator

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

OTHER

lead

Université de Sherbrooke

OTHER

NCT06843148 - Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver. | Biotech Hunter | Biotech Hunter